Levosimendan: evolution over last two decades
Loading...
Date
2022-03
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Medip Academy
Abstract
Levosimendan was maiden agent at the time of its emergence, promoting inotropy mainly through calcium sensitization of cardiac troponin C(cTnC). Levosimendan seems a lucrative option but has not demonstrated a clear superiority to other inotropes in well-designed trials. We searched the PubMed database and reviewed the pertinent studies published till 2021 and summarized various trials/studies to come to a consensus regarding its indications in cardiac patients.Patients with decompensated heart failure requiring inotropic support and receiving beta-blockers represent most widely accepted indication. Levosimendan infusions are increasingly used to facilitate extracorporeal membrane oxygenation (ECMO) weaning and avoiding hospitalizations in patients with end-stage heart failure. Levosimendan doesnę° seem to have long term survival benefit in ventricular dysfunction patients undergoing surgery. The evidence supporting therole in right ventricular failure is not well-established.These lines of evidence require further investigation and their clinical significance needs to be evaluated in specifically designed prospective trials.
Description
Keywords
Levosimendan, Heart failure, ECMO, LV dysfunction, Sepsis, Cardiorenal syndrome
Citation
Gupta Kishore, Shah Dhiren, Naik Dhaval. Levosimendan: evolution over last two decades. International Journal of Advances in Medicine. 2022 Mar; 9(3): 376-383